{"filings":[{"id":2300398,"accession_number":"0001193125-26-354026","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2026-08-17T20:05:15+00:00","items":["8.01"],"status":"ready","headline":"Ardelyx CCO Eric Foster resigns effective Aug 28, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Foster notified Ardelyx on Aug 11, 2026 of resignation as Chief Commercial Officer.","Resignation effective August 28, 2026; Foster leaves to pursue a pre-commercial company opportunity.","Company states resignation is not due to any disagreement with Ardelyx."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2105971,"accession_number":"0001437402-26-000043","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2026-08-06T20:09:56+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Ardelyx Q2 revenue up 31% to $118.1M; cuts FY2026 IBSRELA guidance to $350-370M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total product revenue $118.1M (+31% YoY); IBSRELA $86.2M (+33%), XPHOZAH $31.9M (+27%).","Net loss $16.7M ($0.07/sh) vs $19.1M ($0.08) prior year; cash $281.8M.","FY2026 IBSRELA guidance revised to $350-370M; XPHOZAH reiterated $110-120M; OPEX below $500M.","Long-term IBSRELA $1B target remains but timing uncertain; XPHOZAH long-term guidance pulled.","Drew $50M from SLR facility; CMS lawsuit dismissed, not appealing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1417161,"accession_number":"0001437402-26-000033","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2026-07-02T21:00:53+00:00","items":["2.03","9.01"],"status":"ready","headline":"Ardelyx draws $50M Term F Loan from SLR Investment Corp. for general corporate purposes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Received $50.0M Term F Loan on June 29, 2026, under existing loan agreement with SLR Investment Corp.","Maturity July 1, 2030; interest rate of 4.55% + greater of 1-month SOFR or 3.5%.","Interest-only payments until maturity; proceeds for general corporate purposes and strategic initiatives.","Loan contains customary events of default; default interest rate of 4.0% per annum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1113197,"accession_number":"0001437402-26-000029","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2026-06-17T21:00:54+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Ardelyx stockholders approve 9M share increase to equity plan, re-elect three directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment increasing share reserve under 2014 Equity Plan by 9M to 77.46M shares.","Class III directors Robert Bazemore, Muna Bhanji, and Richard Rodgers re-elected to board until 2029.","Non-binding say-on-pay proposal approved with 137.6M votes for; say-on-frequency set at every one year.","Ratification of Ernst & Young as independent auditor for FY2026 approved with 186.2M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92859,"accession_number":"0001437402-26-000021","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Ardelyx Q1 revenue $93.4M (+38% YoY); IBSRELA revenue $70.1M (+58% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $37.6M ($0.15/sh) vs $41.1M ($0.17/sh) Q1 2025; share-based comp $14.2M.","Cash & investments $238.1M as of Mar 31, 2026; reiterated FY 2026 IBSRELA guidance $410-430M.","IBSRELA Phase 3 CIC trial (ACCEL) enrolling; topline data expected H2 2027.","Appointed Rajani Dinavahi, M.D. as CMO and Felecia Ettenberg, Esq. as CLO in April.","Refinanced debt with SLR Investment Corp for better terms; Morgan Stanley advised."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":94473000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104048,"accession_number":"0001437402-26-000012","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Ardelyx reports 2025 revenue $407.3M; IBSRELA up 73% to $274.2M; guides 2026 higher","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["IBSRELA revenue $274.2M in 2025 (+73% YoY); Q4 $86.6M (+61% YoY).","XPHOZAH revenue $103.6M in 2025; 2026 guidance $110-120M.","Total 2025 revenue $407.3M; net loss $61.6M ($0.26 loss per share).","Cash $264.7M at Dec 31, 2025; fully capitalised for current plans.","Phase 3 ACCEL trial for tenapanor in CIC dosed first patient; topline H2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":407320000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104047,"accession_number":"0001437402-26-000003","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Ardelyx reports preliminary Q4 2025 IBSRELA sales ~$87M, XPHOZAH ~$28M; cash $265M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited U.S. net product sales: IBSRELA ~$87M Q4, ~$274M FY 2025.","Preliminary unaudited U.S. net product sales: XPHOZAH ~$28M Q4, ~$104M FY 2025.","Cash, cash equivalents and short-term investments ~$265M as of Dec 31, 2025, unaudited.","All figures are preliminary and subject to adjustment upon final audited results."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":407320000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120330,"accession_number":"0001437402-25-000021","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Ardelyx CLO and CMO resign effective Dec 31; interim CMO appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elizabeth Grammer resigns as Chief Legal and Administrative Officer effective Dec 31, 2025; will serve as General Counsel then Senior Advisor for 24 months.","Edward Conner resigns as CMO effective Dec 31, 2025 for personal reasons; Dr. Laura Williams appointed interim CMO.","Grammer transition agreement: retains base salary, target bonus 45% for 2025, no ongoing bonus as advisor; equity continues vesting.","Laura Williams, former CMO and current Chief Patient Officer, serves as interim CMO until permanent hire."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120329,"accession_number":"0001437402-25-000016","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx Q3 2025: product revenue $105.5M, IBSRELA +92% YoY, guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q3 product revenue $105.5M (+15% YoY); net loss $1.0M ($0.00 per share).","IBSRELA revenue $78.2M (+92% YoY, +20% QoQ); 2025 guidance raised to $270-275M.","XPHOZAH revenue $27.4M (+9% QoQ); YoY decline due to loss of Part D coverage.","Cash $242.7M; new NHE3 inhibitor RDX10531 with IND submission targeted for 2026.","Appointed Sue Hohenleitner as CFO effective Nov 4, plus new CMO and CTO in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":282105000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120328,"accession_number":"0001437402-25-000008","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ardelyx appoints Sue Hohenleitner as CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Sue Hohenleitner as CFO effective Nov 4, 2025; she joins Oct 13, 2025.","Hohenleitner previously VP & CFO of J&J Innovative Medicine NA ($36B business).","Annual base salary $550,000, target bonus 45% of base, sign-on bonus $180,000.","Received option to purchase 578,104 shares at $5.01/share and 146,896 RSUs, four-year vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136907,"accession_number":"0001628280-25-037441","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","5.02","5.03","9.01"],"status":"ready","headline":"Ardelyx Q2 revenue $97.7M (+33%), raises IBSRELA guidance; CFO to depart","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $97.7M (+33% YoY); IBSRELA net sales $65M (+84% YoY); XPHOZAH net sales $25M (-33% YoY).","Raised FY2025 IBSRELA U.S. net sales revenue outlook to $250-260M from prior guidance.","Net loss $19.1M ($0.08/sh) vs $16.5M ($0.07) YoY; cash & investments $238.5M at June 30, 2025.","CFO Justin Renz to transition out by Dec 31, 2025 or upon new CFO start; transition agreement signed.","Drew $48.7M net from SLR term loan; option to draw additional $100M in two tranches."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":171776000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136906,"accession_number":"0001628280-25-034132","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ardelyx draws $50M term loan, secures $100M additional capacity from SLR","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Immediate draw of $50.0M (Term E Loan) under Fifth Amendment to 2022 Loan Agreement.","Option to draw $100.0M in two $50.0M tranches (Term F & G), available through June 2026 and Dec 2026.","Term E interest: 4.00% + 1-month SOFR (floor 4.70%); Incremental loans: 4.95% + SOFR (floor 3.50%).","Term E and existing loans mature July 1, 2028; Incremental loans mature July 1, 2030; interest-only periods.","Company paid $250K funding fee on Term E and $1.0M facility fee on Incremental loan commitments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154150,"accession_number":"0001628280-25-032172","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Ardelyx shareholders approve equity plan amendment increasing share reserve by 10M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved first amendment to 2014 equity plan, raising authorized shares from 58.5M to 68.5M.","David Mott (92.1M for) and Michael Raab (101.2M for) elected as Class II directors.","Say-on-pay proposal approved with ~91% of votes cast in favor (131.3M for).","Ratification of Ernst & Young as independent auditor for FY2025 approved (182.5M for).","Approximately 187.2M shares voted out of 239.3M outstanding; broker non-votes were 44.1M on most proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154149,"accession_number":"0001628280-25-021514","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx reports Q1 2025 total revenue $74.1M (+61% YoY); IBSRELA $44.4M, XPHOZAH $23.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $74.1M (+61% YoY); net loss $41.1M ($0.17 loss per share) vs $26.5M loss in Q1 2024.","IBSRELA net product sales $44.4M (+57% YoY); FY2025 guidance reaffirmed at $240–250M.","XPHOZAH net product sales $23.4M (+30% ex-returns reserve); $5.0M milestone from Fosun for China tenapanor approval.","Cash $214.0M (Dec 2024: $250.1M); SG&A $83.2M, R&D $14.9M.","Appointed Merdad Parsey to Board and Laura Williams as Chief Patient Officer in April 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":74114000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154148,"accession_number":"0001628280-25-020477","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ardelyx appoints Merdad Parsey to Board of Directors, effective April 28, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Merdad Parsey, M.D., Ph.D., appointed as Class I director, effective April 28, 2025.","Also appointed to Nominating and Corporate Governance Committee effective June 18, 2025.","Initial equity compensation: option and RSUs each valued at ~$225,000, plus annual cash retainers of $50k (board) and $5k (committee).","Dr. Parsey is independent per Nasdaq Listing Rule 5605."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172753,"accession_number":"0001628280-25-006564","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx reports FY2024 revenue $333.6M; narrows net loss to $39.1M; provides 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $333.6M in 2024, up from $124.5M in 2023; driven by IBSRELA ($158.3M) and XPHOZAH ($160.9M) sales.","Net loss narrowed to $39.1M ($0.17 per share) from $66.1M ($0.30 per share) in 2023.","Cash and investments ended at $250.1M; drew $49.7M under term loan in Q4 2024.","IBSRELA 2025 net sales guidance: $240–250M; reaffirmed peak combined sales potential of $1.75B.","SG&A expenses rose to $258.7M from $134.4M due to sales team expansion and XPHOZAH launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":333615000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172752,"accession_number":"0001628280-25-001246","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Ardelyx reports preliminary Q4 2024 net product sales: IBSRELA $54M, XPHOZAH $57M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["IBSRELA net product sales: ~$54M in Q4 2024, ~$158M full year.","XPHOZAH net product sales: ~$57M in Q4 2024, ~$161M full year.","Cash, cash equivalents, and short-term investments: ~$250M as of Dec 31, 2024 (unaudited)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":333615000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189774,"accession_number":"0001628280-24-048258","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ardelyx appoints Joseph Reilly as Principal Accounting Officer effective Nov 15, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph Reilly, age 51, appointed Principal Accounting Officer, replacing Robert Felsch.","Reilly previously SVP Finance at Ardelyx; spent 15+ years at Bristol Myers Squibb and a decade at EY.","Felsch remains with Ardelyx as a senior financial advisor to ensure smooth transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189773,"accession_number":"0001628280-24-044547","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx Q3 revenue $98.2M; IBSRELA $40.6M, XPHOZAH $51.5M; net loss $0.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["IBSRELA Q3 net sales $40.6M (+15% QoQ); full-year guidance set at $145-150M.","XPHOZAH Q3 net sales $51.5M (+39% QoQ); strong launch continues.","Total revenue $98.2M (up 74% YoY); net loss $0.8M vs net income $6.6M in Q3 2023.","Cash $190.4M at Sep 30; drew $49.7M from SLR loan (SOFR+4.02%) in October.","Appointed Eric Foster as CCO in August; CMS Part D change for XPHOZAH cited as 2025 headwind."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":217486000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189772,"accession_number":"0001628280-24-042602","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ardelyx signs lease for 15,012 sq ft Newark office; existing Fremont lease amended","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial 39-month term starting ~Feb 10, 2025; one 60-month extension option.","Initial base rent $3.15/sq ft/month ($47,288/month); 3.5% annual escalations.","Sixth amendment extends existing Fremont lease to later of March 10, 2025 or new lease commencement.","Landlord will fund tenant improvements; tenant responsible for change-request costs.","Lease includes $141,863 letter of credit requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206280,"accession_number":"0001628280-24-036749","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ardelyx enters commercial supply agreement with Catalent for IBSRELA through 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement covers tableting, testing, release and bulk packaging of IBSRELA (tenapanor HCl) at Catalent's Winchester, KY facility.","Initial term through Dec 31, 2028, with automatic renewal for two-year terms thereafter.","Minimum purchase commitment: minimum number of batches per contract year.","Unit pricing adjusted annually starting Jan 1, 2025, based on producer price index.","Either party can terminate for material breach after cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206279,"accession_number":"0001628280-24-034110","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx Q2 total revenue $73.2M, driven by IBSRELA $35.4M and XPHOZAH $37.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["IBSRELA Q2 net sales $35.4M, up ~25% QoQ; XPHOZAH Q2 net sales $37.1M, up from $15.2M in Q1 2024.","Total revenue $73.2M vs $22.3M YoY; net loss narrowed to $16.5M ($0.07/sh) from $17.1M ($0.08/sh) YoY.","FY 2024 IBSRELA revenue guidance unchanged at $140-150M; cash and investments $186M at quarter end.","Filed lawsuit against CMS over ESRD PPS rule threatening XPHOZAH access; declined TDAPA application.","SG&A expenses doubled to $64.7M primarily due to ongoing commercialization of both products."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":119245000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206278,"accession_number":"0001628280-24-030708","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ardelyx opts out of CMS TDAPA for XPHOZAH, foregoing add-on payment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Ardelyx will not apply to include XPHOZAH (tenapanor) in CMS ESRD PPS TDAPA program.","Decision aimed at preserving patient access to the phosphate absorption inhibitor.","By opting out, XPHOZAH will not receive transitional add-on payment from Medicare.","Announcement made on July 2, 2024; no financial guidance provided on impact.","Company expects to rely on standard ESRD PPS bundled payment for XPHOZAH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223358,"accession_number":"0001628280-24-028413","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Ardelyx shareholders approve amended equity plans at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment and restatement of 2014 Equity Incentive Award Plan (78.3M for, 46.1M against).","Stockholders approved amendment and restatement of 2014 Employee Stock Purchase Plan (119.8M for, 4.6M against).","Class I directors William Bertrand and Onaiza Cadoret-Manier elected until 2027 (over 100M votes for each).","Non-binding say-on-pay approved (116.2M for, 7.7M against) and Ernst & Young ratified as auditor (167.1M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223357,"accession_number":"0001628280-24-024996","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ardelyx CCO Susan Rodriguez resigns; stays in advisory role through 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Susan Rodriguez resigned as Chief Commercial Officer on May 22, 2024, by mutual agreement with Ardelyx.","She will continue in an advisory capacity through the end of 2024 to support the transition.","No successor has been announced as of the filing date.","Rodriguez's departure is effective immediately but she remains available for consultation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223356,"accession_number":"0001628280-24-019986","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx Q1 product revenue $45.6M (IBSRELA $28.4M, XPHOZAH $15.2M); net loss $26.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 product-related revenue $45.6M: IBSRELA $28.4M (+149% YoY), XPHOZAH $15.2M (first full quarter after Oct 2023 approval).","Net loss $26.5M ($0.11/sh) vs $26.8M ($0.13/sh) in Q1 2023; cash & investments $202.6M.","Full-year 2024 IBSRELA net sales guidance raised to $140M-$150M.","SG&A expenses $53.0M (+$26.2M YoY) due to commercialization of both products.","Appointed Mike Kelliher as EVP Corporate Development and Strategy in March 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":46023000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242820,"accession_number":"0001628280-24-008908","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["2.03","9.01"],"status":"ready","headline":"Ardelyx draws $50M Term C Loan under existing SLR credit facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Received $50.0 million on March 1, 2024 as Term C Loan under 2022 Loan Agreement with SLR Investment Corp.","Loan matures March 1, 2027; interest rate of 4.25% plus 1-month CME Term SOFR (floor 4.7%).","Interest-only payments permitted until December 31, 2026.","Loan secured by cash and other collateral; customary events of default with 4% default interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242819,"accession_number":"0001628280-24-006321","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx reports FY2023 revenue $124.5M; IBSRELA sales $80.1M, guides 2024 $140-150M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["IBSRELA net product sales $80.1M in FY2023, Q4 $28.1M (+26% QoQ); guides 2024 sales $140-150M.","XPHOZAH launch nets $2.5M in Q4 2023; initiated real-world study.","Total revenue $124.5M in 2023 (up 138% YoY from $52.2M); net loss $66.1M ($0.30 per share).","Cash and investments $184.3M at year-end, up from $123.9M; drew $22.4M from SLR term loan.","Kyowa Kirin launched PHOZEVEL (tenapanor) in Japan Feb 20, 2024; Ardelyx received $3M milestone from Fosun."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":124456000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242818,"accession_number":"0001628280-24-000772","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx reports preliminary Q4 2023 IBSRELA net sales of ~$28M, full year ~$80M, and XPHOZAH ~$2.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IBSRELA US net sales: Q4 ~$28M, FY2023 ~$80M (unaudited).","XPHOZAH US net sales: Q4 ~$2.5M (unaudited).","Cash and investments ~$184M as of Dec 31, 2023 (unaudited)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260198,"accession_number":"0001628280-23-038599","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Geoffrey A. Block resigns from Ardelyx board effective Nov 13, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Block notified the board of his resignation on November 13, 2023, effective immediately.","Resignation is not due to any disagreement with Ardelyx on operations, policies, or practices.","Dr. Block had served on the board since March 2019; no replacement was announced.","He also resigned from the Nominating and Governance Committee upon departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260197,"accession_number":"0001628280-23-035596","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx reports Q3 net income $6.6M; IBSRELA sales $22.3M; raises FY guidance to $76-78M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net income $6.6M ($0.03/share) vs net loss $22.9M in Q3 2022; total revenue $56.4M vs $5.0M.","IBSRELA U.S. net sales $22.3M (22% QoQ growth); FY 2023 guidance raised to $76-78M.","XPHOZAH FDA approved Oct 17, 2023; commercial launch underway, product in channel early Nov.","Cash, cash equivalents & short-term investments $165.1M at Sep 30; ~$218.1M as of Oct 30.","Received $30M milestone from Kyowa Kirin for Japan approval; drew $22.5M from SLR loan amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":90093000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260196,"accession_number":"0001628280-23-034587","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2023-10-18T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Ardelyx secures up to $100M additional debt; $50M committed Term C loan drawable by Mar 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Third Amendment adds $22.5M Term B loan (existing commitment) and $50M committed Term C loan drawable by March 15, 2024.","Uncommitted $50M Term D loan available through Dec 2026, subject to SLR investment committee approval.","Interest rates: Term A/B at SOFR + 7.95% (floor 1.00%); Term C/D at SOFR + 4.25% (floor 4.70%); maturity extended to March 1, 2027.","Interest-only period for existing tranches extended to Dec 31, 2026 upon drawing Term B loan; prepayment premiums: 3%/2%/1% declining.","Term B loan draw conditioned on FDA approval of tenapanor for hyperphosphatemia by Nov 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260195,"accession_number":"0001628280-23-034537","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2023-10-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ardelyx announces FDA approval of XPHOZAH (tenapanor) for hyperphosphatemia in dialysis patients","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved XPHOZAH to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy.","Indicated for patients with inadequate response to phosphate binders or intolerant of any dose.","XPHOZAH is a single tablet taken twice daily with a first-in-class mechanism blocking phosphate absorption.","Approval date: October 17, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277483,"accession_number":"0001628280-23-032952","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2023-09-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ardelyx receives $30M milestone payments from Kyowa Kirin on Japan approval of tenapanor","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Kyowa Kirin received MHLW approval in Japan for tenapanor for hyperphosphatemia in adult CKD patients on dialysis.","Approval triggers $30M in milestone and amendment payments from Kyowa Kirin to Ardelyx.","Ardelyx also receives $5M from HealthCare Royalty Partners under its existing agreement.","Ardelyx may receive an additional $5M from HealthCare Royalty Partners if net sales in Japan exceed a target by 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277482,"accession_number":"0001628280-23-026568","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx Q2 2023: IBSRELA rev $18.3M (+61% QoQ), net loss $17.1M, FY23 guidance $72-77M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["IBSRELA net sales $18.3M in Q2 2023, up 61% QoQ from $11.4M in Q1.","Total revenues $22.3M (incl $4.0M licensing); net loss $17.1M ($0.08/sh) narrowed from $26.9M loss in Q2 2022.","FY2023 IBSRELA net sales guided to $72-77M; management sees $500M+ peak sales potential.","XPHOZAH NDA under FDA review (PDUFA Oct 17, 2023); launch prep underway for Q4 2023 pending approval.","Cash $127.6M at June 30, 2023; raised $11.6M via ATM in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":33702000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295421,"accession_number":"0001628280-23-022681","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Ardelyx shareholders approve increase in authorized common stock from 300M to 500M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Charter amendment filed June 16, 2023; authorized shares increase to 500M from 300M.","Proposal approved with 117.4M for, 38.6M against, 247k abstentions.","Class III directors elected: Bazemore, Bhanji, Rodgers; each received >87M votes for.","Say-on-pay approved on non-binding basis (91.6M for, 14.6M against).","Ernst & Young ratified as independent auditor for FY2023 (152.1M for, 3.2M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295420,"accession_number":"0001628280-23-018655","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2023-05-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ardelyx FDA accepts XPHOZAH resubmission; PDUFA Oct 17, 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted resubmission of NDA for XPHOZAH (tenapanor) for serum phosphate control in dialysis patients.","FDA designated class 2 review with six-month review period; user fee goal date October 17, 2023.","Ardelyx expects XPHOZAH to be commercially available in Q4 2023 following potential FDA approval.","NDA supported by over 1,200 patients in Phase 3 trials (PHREEDOM, BLOCK, AMPLIFY) that met primary endpoints."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295419,"accession_number":"0001628280-23-015205","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx Q1 IBSRELA sales $11.4M, net loss $26.8M; XPHOZAH NDA resubmitted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["IBSRELA net product sales $11.4M in Q1 2023, up from $0.5M in Q1 2022.","Net loss $26.8M ($0.13/share) vs $28.1M ($0.21/share) in prior-year period.","Cash and investments $130.4M as of March 31, 2023; raised $51.9M from ATM offering.","XPHOZAH NDA resubmitted to FDA on April 17, 2023 for phosphate control in CKD patients on dialysis.","Licensed TGR5 agonist portfolio to METiS Therapeutics for $750K upfront + up to $243M milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":11369000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315969,"accession_number":"0001628280-23-006039","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx reports FY2022 net loss $67.2M; IBSRELA sales $15.6M; XPHOZAH NDA resubmission expected early Q2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2022 was $67.2M ($0.42/share) vs $158.2M ($1.52/share) in 2021.","IBSRELA net product sales $15.6M for FY2022, with $8.7M in Q4; consistent prescription growth.","Cash and investments $123.9M at Dec 31, 2022; $121.0M at Feb 28, 2023 (includes $20M ATM proceeds).","XPHOZAH NDA resubmission on track for early Q2 2023 after productive FDA Type A meeting.","Debt facility amended: interest-only period may extend to Mar 2025; additional $22.5M available contingent on FDA approval and revenue targets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315968,"accession_number":"0001628280-23-003565","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2023-02-15T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Ardelyx amends SLR loan; extends interest-only and draw deadlines conditional on FDA tenapanor decision","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Interest-only period extended to April 1, 2025 if FDA approves tenapanor hyperphosphatemia NDA by Nov 30, 2023 or 2023 revenue milestones met.","Draw period for additional $22.5M Term B Loan extended to Dec 20, 2023, tied to same FDA approval timeline.","Interest rate revised to 7.95% + greater of 1% or (0.022% + 1-month CME Term SOFR).","Amendment provides financial flexibility while awaiting FDA decision on tenapanor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315967,"accession_number":"0001193125-23-014238","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2023-01-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ardelyx enters into $150M at-the-market equity offering agreement with Jefferies","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["ATM program allows Ardelyx to sell up to $150M of common stock through Jefferies over time.","Shares will be issued under a new shelf registration statement (S-3) filed Jan 19, 2023, not yet effective.","Jefferies will receive up to 3% commission on gross proceeds from any sales.","Either party may terminate the agreement with 5 trading days' notice.","No assurance of any sales; actual timing and pricing depend on market conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334277,"accession_number":"0001628280-22-032662","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2022-12-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ardelyx receives FDA appeal grant for XPHOZAH; plans NDA resubmission in H1 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Dec 27, 2022, FDA OND granted appeal of July 2021 CRL for XPHOZAH (tenapanor) after Nov 16 CRDAC favorable vote.","OND directs Division of Cardiology and Nephrology to work with Ardelyx on label development for hyperphosphatemia insufficiently managed on binder therapy.","Company expects to resubmit NDA in H1 2023; review classification (Class 1: 2 months, Class 2: 6 months) to be determined post-resubmission.","This reverses prior complete response letter and represents a major regulatory milestone for Ardelyx's only late-stage candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334276,"accession_number":"0001628280-22-028174","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx Q3 2022 net loss $22.9M; IBSRELA sales $4.9M; expects $35M Japan milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.9M ($0.14 per share) versus $43.6M ($0.42) in Q3 2021; narrowed 47%.","IBSRELA net product sales of $4.9M for Q3 2022, six months into launch.","Cash, equivalents and investments $90.6M at Sept 30, 2022, down from $116.7M at Dec 31, 2021.","Kyowa Kirin submitted tenapanor NDA in Japan; Ardelyx expects aggregate $35M milestones in Q4 2022.","FDA Advisory Committee for XPHOZAH (tenapanor) scheduled for November 16, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":7980000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351696,"accession_number":"0001628280-22-025133","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2022-09-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ardelyx regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter confirming compliance with Listing Rule 5450(a)(1).","Closing bid price at or above $1.00 for 10 consecutive business days.","Must maintain bid above $1.00 for 30 consecutive days to stay compliant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351695,"accession_number":"0001628280-22-021051","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx Q2 net loss narrows to $26.9M; IBSRELA sales start at $1.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales of IBSRELA were $1.6M in Q2 2022, first commercial quarter post-launch.","Net loss $26.9M ($0.19/share) vs $45.2M ($0.45) in Q2 2021; cash & investments $81.0M.","Entered $20M financing with HealthCare Royalty based on future royalties from Kyowa Kirin.","FDA advisory committee for XPHOZAH NDA tentatively scheduled for Nov 16, 2022.","Survey data: 41% of GIs report using IBSRELA; 92% rate it as a substantial/moderate advance."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":2994000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351694,"accession_number":"0001628280-22-018940","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2022-07-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ardelyx shareholders reject reverse stock split; Nasdaq listing at risk","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split proposal failed: 63.5M for (44% of outstanding), 33.4M against, insufficient to meet >50% threshold.","Company received Nasdaq deficiency notice on May 23, 2022, for bid price below $1.00; 180-day grace period to comply.","Board authorized to consider options to regain compliance or preserve listing, but no assurances given.","Meeting reconvened solely for Proposal No. 2; original meeting adjourned due to low turnout."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369124,"accession_number":"0001628280-22-018242","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2022-06-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ardelyx sells up to $20M in tenapanor Japan royalties to HealthCare Royalty","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $20M total: $10M upfront, $5M on Japan regulatory approval for hyperphosphatemia, $5M if net sales exceed target by end of 2025.","Royalties stem from Ardelyx's License Agreement with Kyowa Kirin for tenapanor in Japan.","Agreement includes customary covenants restricting sale, lien, or forgiveness of the royalty stream.","Events of default allow HealthCare Royalty to claim indemnification up to a liability cap."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369123,"accession_number":"0001628280-22-017809","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2022-06-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ardelyx adjourns annual meeting on reverse stock split; needs more votes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal to authorize reverse stock split (1:2 to 1:10) received 66.74% of votes cast but needs >50% of outstanding shares; meeting adjourned to July 13.","Stockholders elected Class II directors Block, Mott, Raab; Mott received 42.2M For vs 23.8M Withheld.","Ratification of Ernst & Young as auditor approved (85.7M For, 2.6M Against).","Advisory say-on-pay approved (48.0M For, 14.4M Against, 3.6M Abstain).","As of record date, 144.1M shares outstanding; 91.2M shares voted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369122,"accession_number":"0001628280-22-015564","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2022-05-27T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Ardelyx receives Nasdaq deficiency notice for minimum bid price; seeks reverse stock split approval","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq letter on May 23, 2022, for failure to maintain $1.00 minimum closing bid per share.","Company has 180-day grace period to regain compliance; bid price must close at $1.00+ for 10 consecutive days.","Ardelyx will ask stockholders to approve reverse stock split at June 15, 2022 annual meeting.","If approved, board may effect reverse split by September 15, 2022 to regain compliance.","No assurances of regaining compliance; potential delisting risk remains."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369121,"accession_number":"0001628280-22-012619","cik":1437402,"company_name":"ARDELYX, INC.","ticker":"ARDX","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ardelyx reports Q1 2022 net loss of $28.1M; first IBSRELA sales of $0.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First commercial sales of IBSRELA for IBS-C generated $0.5M in March 2022.","Net loss $28.1M ($0.21 per share) vs $33.2M ($0.34 per share) YoY improvement.","Cash & investments $89.7M at March 31, 2022, down from $116.7M at Dec 31, 2021.","FDA to convene advisory committee for XPHOZAH (phosphate binder) for hyperphosphatemia in CKD on dialysis.","Amended Kyowa Kirin deal: up to $40M additional milestones; royalty rate reduced from high teens to low double digits."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":468000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1558755459.7974067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-05T23:59:59+00:00|369121"}